Your browser doesn't support javascript.
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.
Sakurai, Yasuteru; Ngwe Tun, Mya Myat; Kurosaki, Yohei; Sakura, Takaya; Inaoka, Daniel Ken; Fujine, Kiyotaka; Kita, Kiyoshi; Morita, Kouichi; Yasuda, Jiro.
  • Sakurai Y; Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan; National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, 852-8521, Japan. Electronic address: ysakurai@nagasaki-u
  • Ngwe Tun MM; Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan.
  • Kurosaki Y; Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan; National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, 852-8521, Japan.
  • Sakura T; Department of Molecular Infection Dynamics, Shionogi Global Infectious Diseases Division, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan.
  • Inaoka DK; Department of Molecular Infection Dynamics, Shionogi Global Infectious Diseases Division, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, 852-8523, Japan.
  • Fujine K; Pharmaceutical Research Department, Global Pharmaceutical R&D Division, Neopharma Japan Co., Ltd, Tokyo, 102-0071, Japan.
  • Kita K; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, 852-8523, Japan; Department of Host - Defense Biochemistry, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan. Electronic address: kitak@nagasaki-u.ac.jp.
  • Morita K; Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan. Electronic address: moritak@nagasaki-u.ac.jp.
  • Yasuda J; Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan; National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, 852-8521, Japan. Electronic address: j-yasuda@nagasaki-u
Biochem Biophys Res Commun ; 545: 203-207, 2021 03 19.
Article in English | MEDLINE | ID: covidwho-1068871
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment / Levulinic Acids Type of study: Diagnostic study / Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Biochem Biophys Res Commun Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment / Levulinic Acids Type of study: Diagnostic study / Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Biochem Biophys Res Commun Year: 2021 Document Type: Article